Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Dose Lazertinib and Magnesium for Peripheral Neuropathy in EGFR-Mutant NSCLC
NCT07774520Phase 2Recruiting
- Sponsor
- Samsung Medical Center
- Start
- May 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lazertinib and magnesium in non-small cell lung cancer (NSCLC) and peripheral neuropathy (3 arms), sponsored by Samsung Medical Center. Primary endpoint: Difference of grade 2 or higher peripheral neuropathy up to 36 months. Started May 2026; status: recruiting.
02
Drugs
lazertinibmagnesium
03
Conditions
non-small cell lung cancer (NSCLC)peripheral neuropathy
Beyond the preview
Go deeper on NCT07774520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07774520.